On July 13, 2026, the U.S. Federal Trade Commission (FTC) announced a settlement with Edwards Lifesciences Corp. and JC Medical’s parent company, Genesis MedTech Group Limited, resolving allegations
Abbott (NYSE:ABT) and Edwards Lifesciences (NYSE:EW) said that they have agreed to settle all outstanding patent disputes related to transcatheter mitral and tricuspid repair products, and Edwards
Edwards Lifesciences has secured an important victory before the Unified Patent Court in its long-running heart valve dispute. The Nordic-Baltic division confirmed the patent in amended form and
total 1 pages, 3 items